Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 707 matching trials from the live ClinicalTrials.gov search.
Filters: "mild cognitive impairment" Condition: Alzheimer's Disease Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Macronutrient Effects on Alzheimer's Disease (MEAL-2)

NCT02463084
View directory record Official record
Conditions
Prediabetic State, Insulin Resistance, Middle Age, Prehypertension, Mild Cognitive Impairment
Interventions
Low Diet, High Diet
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
45 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 14, 2026, 1:08 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease

NCT03486938
View directory record Official record
Conditions
Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Interventions
Placebo Oral Tablet, AGB101 220 mg tablet
Drug
Lead sponsor
AgeneBio
Industry
Eligibility
55 Years to 85 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
23
States / cities
Phoenix, Arizona • Laguna Hills, California • Oceanside, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 14, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Results available

Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)

NCT00857506
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • Costa Mesa, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Oct 14, 2026, 1:08 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension

NCT04951284
View directory record Official record
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 14, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

NCT01584440
View directory record Official record
Conditions
Agitation, Alzheimer's Disease
Interventions
AVP-923-20, Placebo, AVP-923-30
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
44
States / cities
Phoenix, Arizona • Sun City, Arizona • Fresno, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 14, 2026, 1:08 AM EDT
Completed Not applicable Interventional

Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults With ADRD

NCT04780178
View directory record Official record
Conditions
Anxiety, Caregiver Burden
Interventions
Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
21 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 14, 2026, 1:08 AM EDT
Completed No phase listed Observational

Brain Attack Surveillance in Corpus Christi--Cognitive (BASIC-Cognitive)

NCT03403257
View directory record Official record
Conditions
Dementia, Dementia Alzheimers, Dementia, Vascular, Dementia, Mixed
Interventions
No interventions
Other
Lead sponsor
University of Michigan
Other
Eligibility
65 Years and older
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 14, 2026, 1:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Wearables

NCT05159557
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment, Alzheimer Disease
Interventions
In-Home Technology System, Limited In-Home Technology
Device
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 14, 2026, 1:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Implications for Management of PET Amyloid Classification Technology

NCT02778971
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Alzheimer's Disease
Interventions
[18F]Flutemetamol
Drug
Lead sponsor
University of Utah
Other
Eligibility
45 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 14, 2026, 1:08 AM EDT
Completed Phase 4 Interventional Results available

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

NCT01951118
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 14, 2026, 1:08 AM EDT
Terminated Phase 1 Interventional

Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease

NCT01482013
View directory record Official record
Conditions
Mild Alzheimer's Disease, Mild Cognitive Impairment
Interventions
HPP854, Placebo
Drug
Lead sponsor
High Point Pharmaceuticals, LLC.
Industry
Eligibility
50 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Miami, Florida • Durham, North Carolina • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Oct 14, 2026, 1:08 AM EDT
Completed Not applicable Interventional Results available

Hearing Aid and Individuals With Cognitive Disorders

NCT04049643
View directory record Official record
Conditions
Presbycusis, Bilateral, Alzheimer Disease 2 Due to Apoe4 Isoform, Mild Cognitive Impairment
Interventions
Audiologist-based fitting, Service-only Fitting, Device-only fitting
Device
Lead sponsor
Yu-Hsiang Wu
Other
Eligibility
55 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 14, 2026, 1:08 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

NCT03887455
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
Lecanemab IV, Placebo, Lecanemab SC
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
112
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 1:08 AM EDT
Completed Phase 2 Interventional

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00876863
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CERE-110: Adeno-Associated Virus injection Surgery, Placebo Surgery
Drug · Procedure
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
55 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 14, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Results available

Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.

NCT00040443
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
CX516, Placebo
Drug
Lead sponsor
RespireRx
Industry
Eligibility
55 Years to 85 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
8
States / cities
Peoria, Arizona • Irvine, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 14, 2026, 1:08 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease

NCT05138848
View directory record Official record
Conditions
Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Sleep, Cognitive Change, Amyloid
Interventions
Time in Bed Restriction, Sleep Schedule
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years to 85 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 14, 2026, 1:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Memory in Mild Cognitive Impairment and Early Stage Alzheimer's Disease

NCT05077826
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
North Coast Medical Activadose II
Device
Lead sponsor
The Mind Research Network
Other
Eligibility
50 Years to 90 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 14, 2026, 1:08 AM EDT
Completed No phase listed Observational

Lactate for Energy and Neurocognition

NCT05207397
View directory record Official record
Conditions
Healthy Aging, Alzheimer Disease
Interventions
Lactate infusion
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
60 Years to 95 Years
Enrollment
24 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 14, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

NCT03533257
View directory record Official record
Conditions
Alzheimer Disease
Interventions
AMX0035, Placebo
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
55 Years to 89 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Jacksonville, Florida • Orlando, Florida • Palmetto Bay, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 14, 2026, 1:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Minocycline in Patients With Alzheimer's Disease

NCT01463384
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Minocycline
Drug
Lead sponsor
Huntington Medical Research Institutes
Other
Eligibility
55 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 14, 2026, 1:08 AM EDT
Recruiting Not applicable Interventional

δ in Dementia Clinical Trials

NCT05592678
View directory record Official record
Conditions
Alzheimer's Disease (AD), Dementia, Cognitive Decline, Mild Cognitivie Impairment (MCI)
Interventions
Donepezil
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 14, 2026, 1:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease

NCT03117738
View directory record Official record
Conditions
Alzheimer Disease
Interventions
AstroStem, Placebo-Control
Drug · Other
Lead sponsor
Nature Cell Co. Ltd.
Industry
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Costa Mesa, California • Santa Ana, California • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 14, 2026, 1:08 AM EDT
Completed Phase 1 Interventional

Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD

NCT02221622
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Allopregnanolone injection (intravenous solution), Placebo injection (intravenous solution)
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 14, 2026, 1:08 AM EDT
Active, not recruiting Not applicable Interventional

48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's Disease

NCT04002583
View directory record Official record
Conditions
Early Onset Alzheimer Disease
Interventions
Computer assisted ambulatory electroencephalogram
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 14, 2026, 1:08 AM EDT